Adjuvant Capecitabine Bests Bolus 5-FU/LV in Patients With Dukes’ C Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 8
Volume 14
Issue 8

ORLANDO-At a median follow-up of 51 months, data reported atASCO from the X-ACT phase III trial

ORLANDO-At a median follow-up of 51 months, data reported atASCO from the X-ACT phase III trialof capecitabine (Xeloda) vs bolus fluorouracil(5-FU)/leucovorin (LV) asadjuvant therapy for patients withDukes' C colon cancer confirm thatadjuvant capecitabine showed consistentbenefits over bolus 5-FU/LV, withat least equivalent disease-free survival(DFS) and a better safety profile,Christopher Twelves, MD, said (abstract3521)."The superior efficacy of capecitabineover 5-FU/LV in metastatic disease(response rate) has translated intosuperior efficacy in the adjuvant setting(relapse-free survival). These findingsprovide a very clear rationale forreplacing 5-FU/LV with capecitabinein the adjuvant treatment of colon cancer,"Dr. Twelves said.The X-ACT trial was undertaken toevaluate the efficacy of capecitabine vs5-FU/LV after studies showed superioractivity and improved safety fororal capecitabine compared with bolus5-FU/LV in first-line metastaticcolorectal cancer. The open-label, multinational,randomized, parallel-groupstudy enrolled 1,987 patients with resectedDukes' C colon carcinoma. Patientswere randomized to receive eitheroral capecitabine (1,250 mg/m2twice daily on days 1-14, every 3 weeks)or IV 5-FU/LV (Mayo Clinic regimen:LV-20 mg/m2 + 5-FU-425 mg/m2 ondays 1-5, every 4 weeks) for 24 weeks.Equivalent DFS, Better RFSThe primary study endpoint was atleast equivalence in DFS. Dr. Twelvessaid that the intent-to-treat analysisshowed at least equivalence in terms ofDFS between the treatment arms, witha strong trend toward superior DFSfor capecitabine (hazard ratio [HR] =0.87; 95% confidence interval [CI],0.75-1.00; P =.0525). At a median follow-up of 53 months, reported followingASCO, 3-year DFS was 66%with capecitabine vs 62.9% with 5-FU/LV (hazard ratio 0.87; P = .055).Relapse-free survival was significantlybetter for capecitabine. The HRof 0.89 translates into a significant14% reduction in risk of relapse withcapecitabine. Capecitabine causedsignificantly (P < .001) less all-gradediarrhea, nausea/vomiting, stomatitis,alopecia, and neutropenia and lessgrade 3/4 neutropenia, stomatitis,and neutropenic fever/sepsis than5-FU/LV. Capecitabine caused morenonlife-threatening hand-foot syndromeand hyperbilirubinemia than5-FU/LV (P < .001).Dr. Twelves concluded, "Multivariateanalysis showed that capecitabinetreatment has a significant impact onDFS (P = .015). The improved safetyprofile of capecitabine in the adjuvantsetting mirrors that observed in themetastatic setting. The high efficacy,improved safety, and convenience ofcapecitabine may increase the proportionof patients able and/or willingto benefit from adjuvant treatment."Adjuvant Xeloda ReceivesFDA ApprovalSince ASCO, the U.S. Food andDrug Administration (FDA) has approvedXeloda for use as single-agentadjuvant therapy following completeresection of the primary tumor forpatients with Dukes' C colon cancerwhen treatment with fluoropyrimidinetherapy alone is preferred. Approvalwas granted after review of datafrom the X-ACT trial (see page 6).

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Related Content